Qiagen
Ad
related to: Sartorius AGsartorius.com has been visited by 10K+ users in the past month
Discover our analytical data package that defines the characteristics of the product. Our product characterization portfolio saves you valuable time and resources.
Search results
Sartorius is part of the solution. We help to ensure that new scientific discoveries can be translated more quickly into effective patient care. With technologies, platforms and partnerships for a common goal: better health for more people.
Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest (Blue chip) stock market index.
Sartorius is a leading international partner for the biopharma sector, offering products and services for drug development and production. Learn about its financial performance, growth strategy, corporate structure and investor relations.
Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability.
Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability.
Based on the slight recovery in demand since the end of the third quarter of 2023 and the market outlook forecast by industry observers, Sartorius expects to grow profitably in 2024 and beyond. 2024
Confidently address increasing demands for enhanced quality, efficiency, accuracy, compliance, and production with instrumentation, intuitive software, hands-on training, and comprehensive services for the biopharmaceutical, chemical, food and beverage industries, and academic sector.
